Cd30 Lymphoproliferative Disorder

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2023-12-05
Clinical Trial Update: Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders [Phase 2]
Phase 2 trial evaluating leflunomide for relapsed or refractory CD30+ lymphoproliferative disorders has completed with results posted.